WHO ICTRP trial
Study to see whether addition of Thalidomide will reduce chemotherapy induced…
CTRI/2021/08/035980 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2021/08/035980 |
|---|---|
| Public title | Study to see whether addition of Thalidomide will reduce chemotherapy induced nausea and vomiting in patients recieving highly emetogenic chemotherapy |
| Scientific title | Thalidomide for the prevention of chemotherapy-induced nausea and vomiting (CINV) in the second cycle among patients receiving Highly Emetogenic Chemotherapy (HEC) and having any nausea in the first cycle: A Randomized, Double-blind, Placebo-controlled trial |
| Primary sponsor | Jawaharlal Institute of Postgraduate Medical Education Research |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: R110- Nausea |
| Interventions | Intervention1: Standard therapy with Thalidomide: Thalidomide 50mg per day is given from day 1 to day 5 of post second chemotherapy cycle along with the standard anti-emetic prophylaxis (Olanzapine, Aprepitant, Ondensetron, Dexamethasone)… |
| Registration date | Aug 26, 2021 |
| Target size | 50 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: